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Objectives The purpose of this study was to compare the safety and efficacy of the Xience V (Abbott Vascular, Santa Clara,
California) everolimus-eluting stent (EES) with the Taxus Liberté (Boston Scientific, Natick, Massachusetts)
paclitaxel-eluting stent (PES) at 2-year follow-up.
Background COMPARE (Comparison of the everolimus eluting XIENCE-V stent with the paclitaxel eluting TAXUS LIBERTE´ stent in all-com-
ers: a randomized open label trial) demonstrated a superior clinical outcome of EES over PES at 1 year in all comers.
Whether this superiority is maintained after discontinuation, at 12months, of dual antiplatelet therapy is unclear.
Methods Patients undergoing percutaneous coronary intervention with limited exclusion criteria were randomly allocated
to EES or PES. The 2-year pre-specified endpoints are composites of safety and efficacy and stent thrombosis.
Results Follow-up was completed in 1,795 of 1,800 patients (99.7%). The groups had similar baseline characteristics. At
2 years, significantly fewer EES patients took dual antiplatelet therapy (11.4% vs. 15.4%, p  0.02). The primary
composite of all death, nonfatal myocardial infarction, and target vessel revascularization occurred in 9.0% of
EES patients and 13.7% of PES patients (relative risk [RR]: 0.66; 95% confidence interval [CI]: 0.50 to 0.86)
driven by a lower rate of myocardial infarction (3.9% vs. 7.5%; RR: 0.52; 95% CI: 0.35 to 0.77) and target vessel
revascularization (3.2% vs. 8.0%; RR: 0.41; 95% CI: 0.27 to 0.62), in parallel with a lower rate of definite or
probable stent thrombosis (0.9% vs. 3.9%; RR: 0.23; 95% CI: 0.11 to 0.49). Differences significantly increased
between 1- and 2-year follow-up for the primary composite endpoint (p  0.04), target vessel revascularization
(p  0.02), and definite or probable stent thrombosis (p  0.02).
Conclusions The substantial clinical benefit of the EES over the PES with regard to measures of both safety and efficacy is main-
tained at 2 years in real-life practice with an increasing benefit in terms of safety and efficacy between 1 year and
2 years. Comparison of the everolimus eluting XIENCE-V stent with the paclitaxel eluting TAXUS LIBERTE´ stent in all-
comers: a randomized open label trial: The COMPARE Trial [COMPARE 1]; NCT01016041) (J Am Coll Cardiol 2011;
58:11–8) © 2011 by the American College of Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2011.02.023Previous randomized trials involving highly selected pa-
tients with either 1 or 2 de novo coronary artery lesions have
shown that the everolimus-eluting stent (EES) has a supe-
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2011, accepted February 22, 2011.rior angiographic outcome in comparison with the
paclitaxel-eluting stent (PES) (1,2). COMPARE (Com-
parison of the everolimus eluting XIENCE-V stent with
the paclitaxel eluting TAXUS LIBERTE´ stent in
See page 26
all-comers: a randomized open label trial) and SPIRIT IV
trials, in less selected patient populations, showed that the
use of EES was associated with a significantly lower rate of
the pre-specified primary endpoints compared to PES (3,4). In
the COMPARE trial, the composite of all death, myocardial
infarction (MI), and target vessel revascularization (TVR)
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2-Year Clinical Outcomes of the COMPARE Trial June 28, 2011:11–8was reduced by 31%. In the
SPIRIT IV (Clinical Evaluation
of the XIENCE V Everolimus
Eluting Coronary Stent System
in the Treatment of Subjects
With de Novo Native Coronary
Artery Lesions) trial, the rate of
target lesion failure (TLF) at 12
months was reduced by 39%. In
addition, both trials showed sig-
nificant decreases in rates of MI,
ischemia-driven target lesion re-
vascularization (TLR), and defi-
nite or probable stent thrombosis
(ST) with EES.
Whether the demonstrated
superiority of EES over PES at 1
year is maintained at 2 years
remains unclear.
Methods
The methodology of the trial has been published previously
(3). In summary, consecutive patients, between 18 and 85 years
f age, referred to Maasstad Ziekenhuis for elective or emer-
ent percutaneous coronary intervention were eligible to par-
icipate. There were no limitations on the number of lesions or
essels, the location of lesions, or their length. Major exclusion
riteria were contraindications to or expected nonadherence to
ual antiplatelet therapy (DAPT) in the 12 months after the
rocedure, planned major surgery within 30 days, and inability
o give informed consent. Patients were assigned on a 1:1 basis
o EES or PES. All patients provided written informed
onsent. The study was investigator-initiated. Funding was
Figure 1 Patient Diagram and Follow-Up
Abbreviations
and Acronyms
CI  confidence interval
DAPT  dual antiplatelet
therapy
EES  everolimus-eluting
stent(s)
MI  myocardial infarction
PES  paclitaxel-eluting
stent(s)
RR  relative risk
SES  sirolimus-eluting
stent(s)
ST  stent thrombosis
TLF  target lesion failure
TLR  target lesion
revascularization
TVR  target vessel
revascularizationrovided by unrestricted research grants from Abbott Vascular
nd Boston Scientific, which had no involvement in the study.
he study was approved by the institutional ethics committee
f the Maasstad Ziekenhuis, Rotterdam, the Netherlands, and
he Dutch Central Committee on Research Involving Human
ubjects (CCMO trial no. NL15206.101.06).
edication. Details of periprocedural oral antiplatelet and
nticoagulant therapy have been published (3). At dis-
harge, all patients were receiving 100 mg of aspirin daily
ndefinitely and 75 mg of clopidogrel daily for 12 months.
tudy endpoints and definitions. Adverse events were
ssessed in the hospital, and at 1, 12, and 24 months. Study
onitors collected data by visits, phone calls, and postal
uestionnaires. Data were stored in our institution. Data
rocessing and adjudication of adverse events, including ST,
ere done in a blinded fashion by an independent contract
esearch organization and core laboratory (Cardialysis, Rot-
erdam, the Netherlands).
The pre-specified primary endpoint was a composite of
ll death, nonfatal MI, and TVR at 12 months. The
econdary endpoints were the primary composite endpoint
t 2-year follow-up and the composite of major adverse
ardiac events (cardiac death, nonfatal MI, and clinically
riven TLR at 2-year follow-up). Definitions of endpoints
re presented elsewhere (3).
tatistical analysis. Categorical variables, including events
etween 1 year and 2 years and up to 2 years, were evaluated
sing the chi-square test or Fisher’s exact test, whereas con-
inuous variables were evaluated with use of Wilcoxon rank-
um test. Events between 1 year and 2 years were evaluated
ith Fisher’s exact test after patients with the specified event
p to 1 year were removed from the analysis.
The time to the pre-specified endpoints was evaluated
ccording to the Kaplan-Meier method, and the log-rank test
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June 28, 2011:11–8 2-Year Clinical Outcomes of the COMPARE Trialwas used to compare endpoint frequencies between groups.
Relative risk (RR) with 95% confidence interval (CI) were
calculated using the normal approximation to the binomial
distribution. The statistical analysis was performed according
to the intention-to-treat principle. All p values were 2-sided,
and a p value 0.05 was considered to indicate statistical
ignificance. Analyses were performed using SAS version 8.02
SAS Institute, Cary, North Carolina).
esults
etween February 2007 and September 2008, 1,800 pa-
ients were enrolled. Randomization and patient flow is
ummarized in Figure 1.
aseline demographic data. Baseline demographic data and
esion characteristics (Table 1) were comparable between
roups (3). A high number of patients presented with an acute
oronary syndrome (59% PES vs. 60% EES). Most lesions
reated were complex (74% type B2 or C), resulting in a mean
tented length of 28 mm in both groups.
linical outcomes. Table 2 shows clinical events at 1- and
-year follow-up. At 2-year follow-up, the primary endpoint
Baseline Patient and Lesion CharacteristicsTable 1 Baseline Patient and Lesion Characteristics
Characteristic
EES
(n  897)
PES
(n  903)
Age, yrs 62.9 63.6
Men 619 (69%) 654 (72%)
Diabetes mellitus* 153 (17%) 172 (19%)
Chronic renal failure† 25 (3%) 24 (3%)
Hypertension 417 (46%) 447 (50%)
Hypercholesterolemia 477 (53%) 451 (50%)
Current smoker 295 (33%) 262 (29%)
Family history of CAD 399 (44%) 403 (45%)
History of MI 136 (15%) 159 (18%)
History of PCI 117 (13%) 123 (14%)
History of CABG 60 (7%) 53 (6%)
Stable angina pectoris 331 (37%) 349 (39%)
Acute coronary syndrome 541 (60%) 534 (59%)
Unstable angina 107 (12%) 105 (12%)
Non–ST-segment elevation MI 194 (22%) 217 (24%)
ST-segment elevation MI 240 (27%) 212 (23%)
Multivessel treatment 244 (27%) 239 (26%)
Treated lesions per patient 1.4 0.7 1.4 0.7
Lesion length 20 mm 290 (32%) 263 (29%)
Number of lesions 1,286 1,294
Stents per lesion 1.7 0.9 1.6 0.9
Stent length per lesion, mm (range) 28 (18–46) 28 (18–44)
Direct stenting 432 (34%) 451 (35%)
Type B2 or C lesion 950 (74%) 955 (74%)
Bifurcation lesions 223 (17%) 237 (18%)
Thrombus present 310 (24%) 314 (24%)
Chronic total occlusion 39 (3%) 53 (4%)
Data are median, n (%), or mean  SD. Percentages have been rounded. *Defined as treatment
ith diet or drugs for previously diagnosed diabetes mellitus. †Defined as serum creatinine 130
mol/l or patient on dialysis.
CABG coronary artery bypass graft surgery; CAD coronary artery disease; EES everolimus-a
eluting stent(s); MI  myocardial infarction; PCI  percutaneous coronary intervention; PES 
paclitaxel-eluting stent(s).Fig. 2A) occurred in 9.0% of the EES group versus 13.7% in
he PES group (RR: 0.66, 95% CI: 0.50 to 0.86, p  0.002).
his reflected a lower rate of both MI and TVR in the EES
roup. All-cause mortality did not differ between groups
Figs. 2B to 2D). Between 1-year and 2-year follow-up, the
vent curves for the primary composite endpoint (p  0.04)
nd TVR (p  0.02) (Table 3) widened significantly.
The secondary endpoint, a composite of cardiac death,
onfatal MI, and TLR, occurred in 7.4% of EES patients
nd 11.3% of PES patients at 2 years (RR: 0.65, 95% CI:
.48 to 0.88, p  0.004). As for the primary endpoint, this
ifference was driven by a reduction in MI and TLR. The
ate of cardiac death did not differ between groups.
In accordance with European percutaneous coronary
ntervention guidelines, the protocol specified that DAPT
hould be prescribed for 1 year after stent implantation. At
year of follow-up, 70% of patients in both groups were
eceiving DAPT. At 2 years, 11.4% of patients in the EES
roup and 15.2% in the PES group (p  0.02) were
eceiving DAPT (Fig. 3).
Definite and probable ST rate differed significantly be-
ween groups at 1 year (0.6% for EES vs. 2.5% for PES, RR:
.22, 95% CI: 0.08 to 0.57, p  0.001). At 2 years of
ollow-up, this absolute difference increased to 3.0% (0.9%
or EES vs. 3.9% for PES, RR: 0.23, 95% CI: 0.11 to 0.49,
 0.001) (Fig. 4). Between 1-year and 2-year follow-up,
this event curve widened significantly (p  0.02) (Table 3).
Early definite and probable ST occurred significantly
ore often in the PES group (0.2% EES vs. 1.7% PES, RR:
.13, 95% CI: 0.03 to 0.59, p  0.002). The rate of late
efinite and probable ST was numerically higher in the PES
roup, but did not differ significantly between groups. The
ate of very late definite and probable ST was significantly
igher in the PES group (0.3% EES vs. 1.4% PES, RR:
.23, 95% CI: 0.07 to 0.81, p  0.01) (Fig. 5).
ubgroup analysis. In a stratified analysis of the primary
ndpoint, the difference between EES and PES was con-
istent across all subgroups apart from patients with diabetes
ellitus, for whom no difference in the primary composite
utcome was noted at 1- or 2-year follow-up; however, the
est of interaction was not significant (Fig. 6).
In a more detailed analysis of the diabetic population, no
ifferences were found in mortality, MI, and ST at 2 years;
owever, significantly more patients had clinically indicated
VR (9.3% vs. 2.0%, RR: 0.20, 95% CI: 0.04 to 0.70, p 
.008), and there was a trend toward more TLR in the PES
roup compared with the EES group (5.8% vs. 2.0%,
espectively; p  0.09).
iscussion
ur major finding was that the demonstrated superiority
t 1 year of EES over PES in terms of safety and efficacy
as maintained at 2 years. Indeed, the event curves
ontinued to diverge in favor of the EES. This difference,
t 2 years, was driven by reductions in both MI and TVR.
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2-Year Clinical Outcomes of the COMPARE Trial June 28, 2011:11–8Clinical Events During Follow-UpTable 2 Clinical Events During Follow-Up
Events
EES
(n  897)
PES
(n  903) RR
Lower
Limit RR*
Upper
Limit RR* p Value
Events at 12 months
Death 18 (2.0) 15 (1.7) 1.21 0.61 2.38 0.58
Cardiac death 11 (1.2) 10 (1.1) 1.11 0.47 2.59 0.81
MI 25 (2.8) 49 (5.4) 0.51 0.32 0.82 0.005
Q-wave 3 (0.3) 11 (1.2) 0.27 0.08 0.98 0.03
Non–Q-wave 22 (2.5) 40 (4.4) 0.55 0.33 0.92 0.02
Death or MI 42 (4.7) 63 (7.0) 0.67 0.46 0.98 0.04
Cardiac death or MI 35 (3.9) 58 (6.4) 0.61 0.40 0.91 0.02
TVR, clinically driven 19 (2.1) 49 (5.4) 0.39 0.23 0.66 0.001
Percutaneous 13 (1.4) 36 (4.0) 0.36 0.19 0.68 0.001
Surgical 6 (0.7) 13 (1.4) 0.46 0.18 1.22 0.11
TVR, any 21 (2.3) 52 (5.8) 0.41 0.25 0.67 0.001
Percutaneous 15 (1.7) 39 (4.3) 0.39 0.22 0.70 0.001
Surgical 6 (0.7) 13 (1.4) 0.46 0.18 1.22 0.11
TLR, clinically driven 15 (1.7) 40 (4.4) 0.38 0.21 0.68 0.001
Percutaneous 9 (1.0) 28 (3.1) 0.32 0.15 0.68 0.002
Surgical 6 (0.7) 12 (1.3) 0.50 0.19 1.34 0.16
TLR, any 18 (2.0) 45 (5.0) 0.40 0.24 0.69 0.001
Percutaneous 12 (1.3) 33 (3.7) 0.37 0.19 0.70 0.002
Surgical 6 (0.7) 12 (1.3) 0.50 0.19 1.34 0.16
Primary endpoint† 56 (6.2) 83 (9.2) 0.68 0.49 0.94 0.02
Secondary endpoint‡ 44 (4.9) 74 (8.2) 0.60 0.42 0.86 0.005
ST, definite and probable 5 (0.6) 23 (2.5) 0.22 0.08 0.57 0.001
Early stent thrombosis, 0–30 days after procedure 2 (0.2) 15 (1.7) 0.13 0.03 0.59 0.002
Late ST, 30 days–1 yr after procedure 3 (0.3) 8 (0.9) 0.38 0.10 1.42 0.13
Definite ST 3 (0.3) 18 (2.0) 0.17 0.05 0.57 0.001
Events at 24 months
Death 30 (3.3) 27 (3.0) 1.12 0.67 1.87 0.67
Cardiac death 20 (2.2) 16 (1.8) 1.26 0.66 2.41 0.49
MI 35 (3.9) 68 (7.5) 0.52 0.35 0.77 0.001
Q-wave 3 (0.3) 17 (1.9) 0.18 0.05 0.60 0.002
Non–Q-wave 32 (3.6) 53 (5.9) 0.61 0.40 0.93 0.02
Death or MI 63 (7.0) 93 (10.3) 0.68 0.50 0.93 0.01
Cardiac death or MI 53 (5.9) 82 (9.1) 0.65 0.47 0.91 0.01
TVR, clinically driven 27 (3.0) 69 (7.6) 0.39 0.25 0.61 0.001
Percutaneous 20 (2.2) 52 (5.8) 0.39 0.23 0.64 0.001
Surgical 7 (0.8) 19 (2.1) 0.37 0.16 0.88 0.02
TVR, any 29 (3.2) 72 (8.0) 0.41 0.27 0.62 0.001
Percutaneous 22 (2.5) 55 (6.1) 0.40 0.25 0.65 0.001
Surgical 7 (0.8) 19 (2.1) 0.37 0.16 0.88 0.02
TLR, clinically driven 23 (2.6) 53 (5.9) 0.44 0.27 0.71 0.001
Percutaneous 16 (1.8) 40 (4.4) 0.40 0.23 0.71 0.001
Surgical 7 (0.8) 15 (1.7) 0.47 0.19 1.15 0.09
TLR, any 26 (2.9) 58 (6.4) 0.45 0.29 0.71 0.001
Percutaneous 19 (2.1) 45 (5.0) 0.43 0.25 0.72 0.001
Surgical 7 (0.8) 15 (1.7) 0.47 0.19 1.15 0.09
Primary endpoint† 81 (9.0) 124 (13.7) 0.66 0.50 0.86 0.002
Secondary endpoint‡ 66 (7.4) 102 (11.3) 0.65 0.48 0.88 0.004
ST, definite and probable 8 (0.9) 35 (3.9) 0.23 0.11 0.49 0.001
Very late ST, 1 yr after procedure 3 (0.3) 13 (1.4) 0.23 0.07 0.81 0.01
Definite ST 5 (0.6) 24 (2.7) 0.21 0.08 0.55 0.001
Values are n (%). *Relative risk (RR) and p values are from the chi-square test. Lower and upper limit of RR represent the 95% confidence intervals. †The pre-specified primary endpoint was a composite
of all death, nonfatal MI and target vessel revascularization (TVR). ‡The principal secondary endpoint was a composite of cardiac death, nonfatal MI, and clinically driven target lesion revascularization (TLR).
ST  stent thrombosis; other abbreviations as in Table 1.
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June 28, 2011:11–8 2-Year Clinical Outcomes of the COMPARE TrialAt 1 year, the EES group showed a significant absolute
risk reduction of 2.6% compared with the PES group in
the rate of a first MI. The magnitude of the difference for
this safety endpoint widened in the subsequent year,
resulting in an absolute risk reduction of 3.6% at 2 years
Figure 2 Kaplan-Meier Cumulative Event Curves for Primary En
Kaplan-Meier cumulative event curves for (A) the primary endpoint, (B) all death,
lute difference in the primary endpoint between groups was 3.0% at 1 year, which
from 2.6% at 1 year to 3.6% at 2 years. The absolute difference in TVR significant
ing stent (PES); blue lines indicate everolimus-eluting stent (EES). PLR  p value a
Outcome Differences Between 1 Year and 2 YeaTable 3 Outcome Differences Between 1 Ye
Outcome
% Patients With Event
and No Even
EES
Primary endpoint 3.0 (25/841)
Death 1.4 (12/879)
Cardiac death 1.0 (9/879)
TVR, clinically driven 0.9 (8/878)
TLR, clinically driven 0.9 (8/882)
MI 1.2 (10/872)
ST, definite and probable 0.3 (3/892)CI  confidence interval; OR  odds ratio; other abbreviations as in Tables 1for the EES group. The COMPARE, SPIRIT III, and
SPIRIT IV trials all showed either a significant reduction
or a trend toward fewer MIs with the EES in the first 30
days (2– 4). That might reflect differences in stent design,
leading to less side branch compromise with the EES (4).
ts
ocardial infarction (MI), and (D) target vessel revascularization (TVR). The abso-
cantly increased to 4.7% at 2 years. The absolute difference in MI increased
ased from 3.5% at 1 year to 4.8% at 2 years. Red lines indicate paclitaxel-elut-
ng to the log-rank test.
d 2 Years
en 1 and 2 Yrs
t Yr
OR 95% CI p ValuePES
5.0 (41/820) 0.58 0.34–0.99 0.04
1.4 (12/888) 1.01 0.41–2.47 1.00
0.7 (6/888) 1.52 0.45–5.21 0.45
2.3 (20/854) 0.38 0.15–0.92 0.02
1.5 (13/863) 0.60 0.21–1.57 0.28
2.2 (19/854) 0.51 0.21–1.16 0.09
1.4 (12/880) 0.24 0.04–0.91 0.02dpoin
(C) my
signifi
ly incre
ccordirsar an
Betwe
t Firsand 2.
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2-Year Clinical Outcomes of the COMPARE Trial June 28, 2011:11–8Our results suggest that other mechanisms may also
contribute. When periprocedural and early (30 days)
events were excluded, we observed that event curves
significantly diverged from the 30-day timepoint up to 2
years (data not shown). A similar trend (p  0.22) was
noted in the pooled SPIRIT II and III trial reports;
between 1- year and 2-year follow-up, MI occurred in
0.8% of EES patients versus 1.7% of PES patients (5).
As previously reported, the rate of ST in the COMPARE
study at 1 year was significantly lower with EES. Between 1
and 2 years, there was a further significant divergence of the
event curves due to a significantly lower definite and probable
Figure 3 Baseline and Follow-Up DAPT
Dual antiplatelet therapy (DAPT) at baseline and at 1, 6, 12, and 24 months of
follow-up in the paclitaxel-eluting stent (PES) group (red bars) and the everoli-
mus-eluting stent (EES) group (blue bars). At 2 years, significantly more
patients were on DAPT in the PES group (*p  0.02).
Figure 4 Kaplan-Meier Cumulative Event Curves for ST at 2-Yea
Kaplan-Meier cumulative event curves for definite and probable stent thrombosis (
difference in rates of definite and probable ST between stent groups was 1.9% at
line indicates EES. Abbreviations as in Figure 2.ST in the EES group, despite low rates of DAPT, which were
not protocol mandated after 1 year. The small, but significantly
higher rate of DAPT in the PES group at 2 years parallels
differences in MI and ST rates, events that likely led to
prolongation or reinstitution of DAPT.
With first-generation DES, the promising low ST rates in
initial clinical trials (6) have shown a consistent increase as the
patient populations enrolled expanded from those with favor-
able “research” lesions to “real-world” lesions. Registry studies
have clearly demonstrated a continuing risk of very late ST,
with annual increments in ST of 0.4% and 0.6% for SES and
PES, respectively (7,8). In our all-comer trial, the annual
increase of definite ST with PES was comparable (0.7%).
Against this background, the ST rates reported with EES to
date are much lower and of the same order of magnitude as for
bare-metal stents (6,7,9). Two-year pooled (892 patients) ST
rates for the SPIRIT II and III studies, with restrictive
inclusion criteria, showed a 1.2% rate of probable or definite
ST, remarkably similar to that of COMPARE (0.9%) (5).
Differences in stent design, strut thickness, delivery plat-
form, polymer coating, drug, and drug release profile could all
play a role in the difference in ST rates between PES and EES.
Other potential explanations may be more rapid re-
endothelialization with EES, documented in the rabbit iliac
model, or the more biocompatible fluorinated copolymer
(10–12).
Both TLR and TVR were significantly lower for EES at
2 years, with relative risk reductions of 55% and 60%,
respectively. Between 1 and 2 years, the absolute difference
llow-Up
2-year follow-up as defined by the Academic Research Consortium. The absolute
, which significantly increased to 3.9% at 2 years. Red line indicates PES; bluer Fo
ST) at
1 year
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June 28, 2011:11–8 2-Year Clinical Outcomes of the COMPARE Trialfor TVR between the PES and EES groups increased
significantly from 3.5 to 4.8%.
The recently published SPIRIT IV trial showed results
for safety and efficacy endpoints similar to those for the
Figure 5 Kaplan-Meier Cumulative Event Curves for Early, Late
Kaplan-Meier cumulative event curves for definite and probable stent thrombosis (ST) in th
Consortium. Red lines indicate PES; blue lines indicate EES. RR  relative risk; other abb
Figure 6 Post-Hoc Subgroup Analysis
Results of a post-hoc subgroup analysis performed with 9 clinical or angiographic
with diabetes mellitus. However, the test for interaction was not significant. ACS 
infarction; RVD  reference vessel diameter.COMPARE trial at 1 year of follow-up (4). At 2-year
follow-up, there was a continuing benefit of EES in TLF
and ST rates. However, no divergence of the curves between
1 and 2 years was observed. Whether the inclusion of
Very Late ST
arly, (B) late, and (C) very late time periods, as defined by the Academic Research
ns as in Figure 2.
les. The treatment effect was consistent across subgroups, apart from patients
e coronary syndrome; LAD  left anterior descending artery; MI  myocardial, and
e (A) e
reviatiovariab
acut
11
1
1
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2-Year Clinical Outcomes of the COMPARE Trial June 28, 2011:11–8patients and lesions at lower risk in the SPIRIT IV study or
the very high rate (72%) of DAPT at 2-year follow-up
might account for this discordance is unclear (13).
Conclusions
In summary, we have shown that the substantial clinical
benefit of the EES Xience V stent over the PES Taxus
Liberté with regard to measures of both safety and
efficacy is maintained at 2 years in real-life practice with
an increasing benefit in terms of safety and efficacy
between 1 and 2 years. Further research is required to
understand the lack of benefit of EES over PES in the
diabetic population.
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